How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

Amazon Q Developer is a useful AI-powered coding assistant with chat, CLI, Model Context Protocol and agent support, and AWS ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...

A maximum severity vulnerability, dubbed 'React2Shell', in the React Server Components (RSC) 'Flight' protocol allows remote code execution without authentication in React and Next.js applications.

Researchers discovered that adding instructions for AI-powered browser assistants after the hash (#) symbol inside URLs can influence their behavior to leak sensitive data and direct users to phishing ...

Jennifer Simonson is a business journalist with a decade of experience covering entrepreneurship and small business. Drawing on her background as a founder of multiple startups, she writes for Forbes ...

Transformer Weekly: Preemption’s out the NDAA, OpenAI’s ‘code red,’ and Anthropic’s IPO prep ...

The Architects of AI drove the economy, shaped geopolitics, and changed the way we interact with the world. by Charlie Campbell, Andrew R. Chow and Billy Perrigo by Sam Jacobs by D.W. Pine ...